Avastin Label Strengthened Following Leukoencephalopathy Cases
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech says syndrome not related to PML found in some MS patients taking Biogen Idec’s Tysabri.
You may also be interested in...
Lucentis SAILOR Trial Hits Choppy Water
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.
Lucentis SAILOR Trial Hits Choppy Water
Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.
Biogen Idec Looks To Develop PML Treatment
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.